Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-10-01 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin gets EIR from U.S. FDA for its Ankleshwar Manufacturing Facility.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of the Establishment Inspection Report (EIR) from the US FDA for Lupin Limited's Ankleshwar manufacturing facility. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is an announcement of a regulatory event rather than a detailed report or financial statement. The document length is 3939 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data, management discussion, or audit information. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2022-10-01 English
Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for Lupin Limited's Abbreviated New Drug Application for Mirabegron Extended-Release Tablets. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product launch, not a financial report, earnings release, or management discussion. The document length is 4178 characters, which is relatively short and primarily an announcement. There is no financial data, no detailed report, no voting results, no management changes, or other regulatory filings. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and disclosure under listing obligations.
2022-09-29 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product. It is addressed to stock exchanges and references a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or detailed management discussion. The document length is 4169 characters, which is relatively short and typical for a press release or regulatory announcement. There is no financial data, no discussion of financial results, no voting results, no management changes, and no detailed report attached or referenced. Therefore, the document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories.
2022-09-29 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Sildenafil for Oral Suspension) by Lupin Limited, including details about FDA approval and product information. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document is short (3847 characters) and does not contain financial statements, detailed financial analysis, or regulatory certifications. It is not an earnings release or financial report but a corporate announcement about a product launch and regulatory approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-29 English
Lupin Launches Sildenafil for Oral Suspension in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Sildenafil for Oral Suspension) by Lupin Limited, including details about FDA approval and product market information. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document is short (3859 characters), contains no financial statements or detailed financial analysis, and is primarily an announcement of a corporate event rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is the actual announcement itself, not a notice about a report release. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2022-09-29 English
Company has received a warning letter from the U.S. FDA for the Company's Tarapur, Maharashtra (India) facility.
Regulatory Filings Classification · 95% confidence The document is a disclosure letter addressed to stock exchanges regarding a warning letter received from the U.S. FDA about the company's manufacturing facility. It references compliance with regulatory standards and is submitted pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements. The document is short (2286 characters) and serves as an announcement of a regulatory communication rather than a detailed report or financial statement. It does not contain financial data, audit information, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.